The multibillion-dollar settlement that the maker of OxyContin is negotiating to settle a crush of lawsuits over the nation’s opioid crisis contains formulas for dividing up the money among state and local governments across the country, The Associated Press has learned.
The formulas would take into account the number of people in a given jurisdiction who misuse opioids, the number of overdose deaths and other factors, according to a person familiar with the talks but not authorized to discuss them publicly.
Spelling out the way the settlement is to be split could forestall squabbles over the money and avoid what some see as the mistakes made with the hundreds of billions of dollars received under the nationwide settlement with Big Tobacco during the 1990s.
Activists have complained that precious little of the money from the tobacco industry went toward anti-smoking programs and too much was diverted toward state budget holes, pensions and other things unrelated to smoking’s toll.
In the case of the opioid litigation, some of the plaintiffs have said they want direct control over the money to make sure it goes toward treating and preventing addiction and covering some of the taxpayer costs associated with the deadly epidemic, including mental health services, police calls and foster care for children of addicts.
Published reports say a $10 billion to $12 billion settlement of the opioid claims is taking shape.
As an example of the proposed formulas, Cabell County, West Virginia, a hard-hit part of Appalachia, and the local governments in it would get a total of $975,000 for every $1 billion in the settlement. Philadelphia would receive $6.5 million.
The talks are being overseen by a federal judge in Cleveland. But Purdue wants any settlement to apply to all claims against it: the nearly 2,000 lawsuits in federal court and the hundreds of other local government and state lawsuits filed in state courts.
Under the plan now on the table, Purdue Pharma would file for bankruptcy and transform itself into a “public benefit trust corporation,” with all profits from drug sales and other proceeds going to the plaintiffs, news reports said.
The Sackler family would give up ownership of Purdue Pharma and contribute a least $3 billion of its money toward the total, the reports said.
Stamford, Connecticut-based Purdue Pharma declined to comment Thursday but said earlier in the week that it sees little good in years of “wasteful litigation and appeals” and believes a far-reaching settlement is the best solution.
Purdue Pharma is privately owned and not required to issue public financial reports. But Decision Resources Group, a healthcare research and consulting firm, estimates Purdue brought in $13.6 billion from 2014 through 2018 just from sales of its OxyContin, Butrans and Hysingla opioid painkillers.
Mulvihill reported from Cherry Hill, New Jersey. Associated Press writer Linda Johnson in Trenton, New Jersey, contributed to this report.